Incyte agrees to acquire Vega Therapeutics for $1.25 billion upfront

Incyte announced it will purchase Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction that includes an upfront payment of $1.25 billion.

The acquisition gives Incyte control of Vega’s Phase 3 candidate for a bleeding disorder, which the companies said is a key asset in their pipeline.

The deal also contains up to $750 million in additional milestone payments, subject to the achievement of certain development and regulatory targets.